Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study.

Ann Gastroenterol · 2023 · PMC10304522 · PMID 37396006

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

These include quite significant nausea and leukopenia, as well as an increased risk of serious infection or cancer, and lymphoma in particular.

also in 5,705 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.